---
title: Image-Guided Tumorboost of Bladder Cancer
nct_id: NCT00963404
overall_status: COMPLETED
phase: PHASE1, PHASE2
sponsor: University of Aarhus
study_type: INTERVENTIONAL
primary_condition: Bladder Neoplasms
countries: Denmark
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00963404.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00963404"
ct_last_update_post_date: 2018-05-03
last_seen_at: "2026-05-12T07:28:39.013Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Image-Guided Tumorboost of Bladder Cancer

**Official Title:** Image-guided Tumorboost of Localized Unifocal Bladder Cancer: A Phase I/II Study

**NCT ID:** [NCT00963404](https://clinicaltrials.gov/study/NCT00963404)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 19
- **Lead Sponsor:** University of Aarhus
- **Collaborators:** Aarhus University Hospital
- **Conditions:** Bladder Neoplasms
- **Start Date:** 2009-08
- **Completion Date:** 2017-01
- **CT.gov Last Update:** 2018-05-03

## Brief Summary

The purpose of the study is to increase the radiation dose (Boost) to the bladder tumor. The bladder cancer patients included in the study will undergo tumor demarcation. The bladder demarcations will then be the target for an image-guided boost delivered precisely to the expected tumor site.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Muscle invasive bladder cancer (transitional carcinoma)
* Unifocal
* TNM stage T2a-4a, N0-1, M0
* unfit for radical cystectomy

Exclusion Criteria:

* Hyperthyroidism
* Multinodular goiter
* Pregnancy
* Breast feeding
* WHO preformance status more than 2
* Iodine allergy
* MRI or CT contrast media allergy
* Bi-lateral hip-prosthesis
```

## Arms

- **Tumor-boost** (EXPERIMENTAL) — Image-guided tumorboost of the bladder cancer.

## Interventions

- **Radiation boost** (RADIATION) — Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.

## Primary Outcomes

- **Local tumor control** _(time frame: One year)_

## Secondary Outcomes

- **Acute and late adverse effects of the radiotherapy treatment** _(time frame: 3 years)_

## Locations (4)

- The department of Oncology, Aarhus University Hospital, Aarhus, Denmark
- The department of Oncology, Rigshospitalet, Copenhagen, Denmark
- The department of Oncology, Herlev University Hospital, Herlev, Denmark
- The department of Oncology, Odense University Hospital, Odense, Denmark

## Recent Field Changes (last 30 days)

- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the department of oncology, aarhus university hospital|aarhus||denmark` — added _(2026-05-12)_
- `locations.the department of oncology, rigshospitalet|copenhagen||denmark` — added _(2026-05-12)_
- `locations.the department of oncology, herlev university hospital|herlev||denmark` — added _(2026-05-12)_
- `locations.the department of oncology, odense university hospital|odense||denmark` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00963404.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00963404*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*